Structural highlights
Publication Abstract from PubMed
The structure-based design, synthesis, and biological evaluation of a series of nonpeptidic HIV-1 protease inhibitors with rationally designed P2' ligands are described. The inhibitors are designed to enhance backbone binding interactions, particularly at the S2'-subsite. Synthesis of inhibitors was carried out efficiently. The stereochemistry of alcohol functionalities of the P2'-ligands was set by asymmetric reduction of the corresponding ketone using (R,R)- or (S,S)-Noyori's catalysts. A number of inhibitors displayed very potent enzyme inhibitory and antiviral activity. Inhibitors 3g and 3h showed an enzyme Ki of 27.9 and 49.7 pM and antiviral activity of 6.2 and 3.9 nM, respectively. These inhibitors also remained quite potent against darunavir-resistant HIV-1 variants. An X-ray structure of inhibitor 3g in complex with HIV-1 protease revealed key interactions in the S2'-subsite.
Design, synthesis, biological evaluation, and X-ray studies of HIV-1 protease inhibitors with modified P2'-ligands of Darunavir.,Ghosh AK, Fyvie WS, Brindisi M, Steffey M, Agniswamy J, Wang YF, Aoki M, Amano M, Weber IT, Mitsuya H ChemMedChem. 2017 Nov 6. doi: 10.1002/cmdc.201700614. PMID:29110408[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ Ghosh AK, Fyvie WS, Brindisi M, Steffey M, Agniswamy J, Wang YF, Aoki M, Amano M, Weber IT, Mitsuya H. Design, synthesis, biological evaluation, and X-ray studies of HIV-1 protease inhibitors with modified P2'-ligands of Darunavir. ChemMedChem. 2017 Nov 6. doi: 10.1002/cmdc.201700614. PMID:29110408 doi:http://dx.doi.org/10.1002/cmdc.201700614
